– BELGIUM, Liege – Mayne Pharma Group Limited, today announced the appointment of Dr. Carolyn Myers to its Board of Directors as a representative of Mithra (EBR: MITRA), a company dedicated to Women’s Health and largest shareholder of Mayne Pharma.
“We are delighted to welcome Carolyn to the Board of Mayne Pharma. Carolyn has a distinguished track record of success in creating, growing, and leading healthcare businesses. She has a deep experience in business development, sales and marketing, strategy, portfolio management and R&D and has led the launch of over 20 brand products.” said Board Chair, Frank Condella.
About Dr. Carolyn Myers
Dr. Carolyn Myers, a U.S. resident, has been supporting Mithra’s business development and marketing strategy for several years. She is an experienced pharmaceutical executive having held senior leadership roles at Allergan, Forest Labs, Mylan (now Viatris), and Pharmacia (now Pfizer). With over 30 years of experience in the pharmaceutical industry, she is currently CEO of FendX technologies, a medical technology company formed to develop and commercialize products using a unique pathogen-repelling technology. She is also Principal of BioEnsemble, providing consulting services to small and mid-size pharma, biotech, and medical technology companies. Previously, she held the positions of VP of Global Alliance Management and International Business Development at Allergan, VP of Marketing at Forest Laboratories, President of Dey Laboratories, and President of Mylan Technologies. She holds a Ph.D. from the University of British Columbia and a Master’s in Business Administration from Rutgers University.
Dr. Myers said: “I am pleased to be joining the Board at this important time in Mayne Pharma’s development. As the nominee of the Company’s largest shareholder, our interests are aligned. I am committed to supporting the successful commercialization of Nextstellis oral contraceptives in the world’s largest pharmaceutical market.”
About Mithra
Mithra is a Belgian biotech company dedicated to transforming Women’s Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra’s goal is to develop products offering better efficacy, safety, and convenience, meeting women’s needs throughout their life span. Mithra explores the potential of the unique native estrogen Estetrol in a wide range of applications in women’s health and beyond (Covid-19, neuroprotection…). Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers. It offers partners a complete spectrum of research, development, and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 300 staff members and is headquartered in Liège, Belgium.
For more information: https://www.mithra.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.